Novo Nordisk has submitted NDAs for what could be the first ever oral...
- NHS Digital finds cost of prescriptions declines, but number of items rises
- AZ and Seres will use gut microbiome to tailor cancer immunotherapy
- ImmunoGen to reassess lead ovarian cancer candidate after FORWARD I flop
- AAD 2019: S. aureus discussed as biomarker for atopic dermatitis
- US Senate invites pharmacy benefit managers to testify on drug pricing
NDAs submitted to the FDA for the first oral GLP-1 receptor agonist
Novo Nordisk has submitted NDAs for what could be the first ever oral GLP-1 based treatment for type II diabetes. What could this mean for the GLP-1 market?
Join Alconox at Cphi North America, Chicago
Visit Alconox at Cphi North America in Chicago to receive its unique gifts and expert technical support for your critical cleaning applications and detergent samples.
Bristol-Myers $74bn Celgene takeover gets shareholders approvals
Bristol-Myers Squibb has secured shareholders’ approval for its $74bn acquisition of biotechnology company Celgene. More than 75% of the shareholders voted in favour of the merger agreement.
Sanofi to slash costs of certain insulin products in US
Sanofi has said that it will reduce the cost of some of its insulin products to $99 per month in a bid to mitigate burden on diabetes patients in the US.
Sandoz to commercialise Shionogi’s Rizmoic in European markets
Novartis unit Sandoz has entered an agreement to commercialise Japanese pharmaceutical company Shionogi’s drug Rizmoic (naldemedine) in the UK, Germany and the Netherlands.
TrialScope: Trial Disclosure Software and Service
This short video explains why 13 of the top 15 pharmaceutical sponsors partner with TrialScope to manage disclosure and registration of more than 30,000 global clinical trials.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.